Friday, July 10, 2026

pharma · Rheumatoid Arthritis · Warm Antibody Autoimmune Hemolytic Anemia · RIGL

RIGEL PHARMACEUTICALS

Rigel Pharmaceuticals is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker RIGL. Primary therapeutic focus areas include Rheumatoid Arthritis, Warm Antibody Autoimmune Hemoly

1180 Veterans Blvd, South San Francisco, CA 94080, US HQ
1996 Founded
286 Employees
Public company Type
RIGL · NYSE Ticker
Company details
Status
Public
HQ
1180 Veterans Blvd, South San Francisco, CA 94080, US
Founded
1996
Employees
286
Programs
36
Drugs
26
Patents
373
Clinical program

GAVRETO ®(pralsetinib) capsules

Approved · small molecule · Patients with advanced or metastatic solid tumors

GAVRETO ®(pralsetinib) capsules for Patients with advanced or metastatic solid tumors is a Approved program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

← All RIGEL PHARMACEUTICALS INC projects Approved small molecule active

Internal code RGL-RET-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
RIGEL PHARMACEUTICALS INC
Phase
Approved
Modality
small_molecule
Indication
Patients with advanced or metastatic solid tumors
Status
active
Trials
1